Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Hematology/Oncology Clinics of North America|June 27, 2021
First-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?Hua-Jay J Cherng, Nitin Jain
Current Treatment Options in Oncology|April 24, 2024
Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma: from Bench to Bedside?Hua-Jay J Cherng, Alex Herrera
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2022
Broadening the MIND: Tafasitamab and Lenalidomide versus Synthetic ControlsHua-Jay J Cherng, Jason R Westin
Current Hematologic Malignancy Reports|November 6, 2023
Measurable Residual Disease Monitoring in LymphomaBrian Cuzzo, Andrew Lipsky, Hua-Jay J Cherng
Clinical Lymphoma, Myeloma & Leukemia|July 24, 2018
Interim PET/CT Result Is Not Predictive of Survival in Patients With MYC-rearranged Non-Burkitt Aggressive B-cell LymphomaHua-Jay J Cherng, Rachel Lynn Sargent, Sunita Dwivedy Nasta, et al.
British Journal of Haematology|May 11, 2021
Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemiaHua-Jay J Cherng, Nadya Jammal, Shilpa Paul, et al.
American Journal of Hematology|May 14, 2022
TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysisHua-Jay J Cherng, Raamis Khwaja, Rashmi Kanagal-Shamanna, et al.
Pageof 2